Mark Bickers, MD
Internal Medicine · Floyds Knobs, INNPI 1710364179
Payments from drug & device makers
Across 473 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$603
- Pfizer$537
- Takeda Pharmaceuticals U.S.A., Inc.$514
- GSK$434
- plus $2K from 31 others
What the payments were for
- Food & beverage$7,09599%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 113 | $1,554 |
| Novo Nordisk | 76 | $1,020 |
| AstraZeneca | 21 | $603 |
| Pfizer | 42 | $537 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $514 |
| GSK | 23 | $434 |
| Boehringer Ingelheim | 17 | $324 |
| Biohaven Pharmaceutical Holding Company Ltd. | 21 | $259 |
| Amgen | 18 | $227 |
| Lilly USA, LLC | 15 | $210 |
| Biohaven Pharmaceuticals, Inc. | 11 | $195 |
| Exact Sciences | 12 | $184 |
| Merck | 8 | $123 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $121 |
| Bayer | 6 | $105 |
| Novartis | 6 | $97 |
| Corium, LLC | 7 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $74 |
| Abbott | 4 | $64 |
| Kowa Pharmaceuticals America, Inc. | 4 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Cranial Technologies, Inc | 2 | $33 |
| Eisai Inc. | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $25 |
| Gilead | 2 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $21 |
| Philips North America LLC | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Dermira, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,150 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $154,181 |
| EliquisApixaban | 134 | $121,683 |
| JardianceEmpagliflozin | 49 | $55,573 |
| XareltoRivaroxaban | 41 | $50,129 |
| VraylarCariprazine Hcl | 33 | $45,353 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 58 | $40,663 |
| RybelsusSemaglutide | 35 | $36,668 |
| ProliaDenosumab | 17 | $29,846 |
| GemtesaVibegron | 36 | $28,526 |
| LinzessLinaclotide | 37 | $26,891 |
| TrulicityDulaglutide | 18 | $26,570 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $25,892 |
| JanuviaSitagliptin Phosphate | 21 | $20,246 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $20,244 |
| TrintellixVortioxetine Hydrobromide | 24 | $16,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,020 | $190,849172 claims |
| PfizerEliquis, Premarin | $537 | $129,439160 claims |
| AbbVieVraylar, Linzess | $1,554 | $72,24470 claims |
| Boehringer IngelheimJardiance | $324 | $55,57349 claims |
| Johnson & JohnsonXarelto | $16 | $50,12941 claims |
| AstraZenecaBreztri Aerosphere | $603 | $40,66358 claims |
| AmgenProlia | $227 | $29,84617 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $42 | $28,52636 claims |
| Lilly USA, LLCTrulicity | $210 | $26,57018 claims |
| GSKTrelegy Ellipta | $434 | $25,89228 claims |
| MerckJanuvia | $123 | $20,24621 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $514 | $16,20024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Floyds Knobs
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.